How to take Vismodegib

Vismodegib (Vismodegib) is indicated for the treatment of adults with metastatic basal cell carcinoma, adults with locally advanced basal cell carcinoma that has relapsed after surgery, or adults who are not candidates for surgery and radiation therapy. Vimodageb is marketed as a 150 mg oral capsule with a recommended dose of 150 mg taken orally once daily until disease progression or unacceptable toxicity occurs.

For intolerable adverse reactions, withhold for up to 8 weeks until symptoms improve or resolve. Treatment should be interrupted if the patient experiences severe cutaneous adverse reactions, severe or intolerable musculoskeletal adverse reactions. For recurrent, severe, or intolerable musculoskeletal adverse reactions, vismodegib should be permanently discontinued. Vimodegib appears to have non-linear pharmacokinetics after daily oral dosing and reaches steady state within 7 days. Increasing the dose from 150 mg to 540 mg (1 to 3.6 times the recommended dose) did not result in an increase in steady-state plasma concentrations. At a once-daily dose of 150 mg, the mean plasma concentration of vismodegib at steady state is approximately 23 M. The absolute bioavailability of vismodegib in a single dose is 31.8%. Absorption is saturated and not affected by food.

The original drug of Vimodegib is not currently on the market in the country, so it cannot be included in medical insurance. Overseas, Vimodegiboriginal drug has Turkish version and European version, specificationsThe price of 150mg*28 capsules per box may be around RMB 10,000-30,000 (the price may fluctuate due to the exchange rate). The price is very expensive, and there are currently no generic versions of Vimodegib. For more drug information and specific prices, please consult Yaodei Medical Consultants.